OPCH vs SGRY vs ACHC vs MCK

For growth investors, McKesson Corporation (MCK) is the stronger pick with 16.

2% revenue growth year-over-year, versus 5. 0% for Acadia Healthcare Company, Inc. (ACHC). Option Care Health, Inc. (OPCH) offers the better valuation at 16. 3x trailing P/E (11. 1x forward), making it the more compelling value choice. Analysts rate Option Care Health, Inc. (OPCH) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Option Care Health, Inc.

(OPCH) is the cheapest at 16. 3x versus McKesson Corporation at 29. 2x. On forward P/E, Option Care Health, Inc. is actually cheaper at 11. 1x.

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.

9%, compared to -72. 3% for Surgery Partners, Inc. (SGRY). Over 10 years, the gap is even starker: MCK returned +348. 1% versus ACHC's -58. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at 0.

04β versus Surgery Partners, Inc. 's 1. 04β — meaning SGRY is approximately 2322% more volatile than MCK relative to the S&P 500. On balance sheet safety, Surgery Partners, Inc. (SGRY) carries a lower debt/equity ratio of 114% versus 124% for Acadia Healthcare Company, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 16.

2% versus 5. 0% for Acadia Healthcare Company, Inc. (ACHC). On earnings-per-share growth, the picture is similar: Surgery Partners, Inc. grew EPS 54. 1% year-over-year, compared to -537. 4% for Acadia Healthcare Company, Inc.. Over a 3-year CAGR, OPCH leads at 12. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Option Care Health, Inc.

(OPCH) is the more profitable company, earning 3. 7% net margin versus -33. 3% for Acadia Healthcare Company, Inc. — meaning it keeps 3. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SGRY leads at 11. 8% versus 1. 2% for MCK. At the gross margin level — before operating expenses — SGRY leads at 23. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Option Care Health, Inc.

(OPCH) trades at 11. 1x forward P/E versus 38. 0x for Surgery Partners, Inc. — 26. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OPCH: 59. 0% to $33. 00.

In this comparison, MCK (0.

4% yield) pays a dividend. OPCH, SGRY, ACHC do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, McKesson Corporation (MCK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

04), +348. 1% 10Y return). Both have compounded well over 10 years (MCK: +348. 1%, SGRY: -0. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: OPCH is a small-cap deep-value stock; SGRY is a small-cap quality compounder stock; ACHC is a small-cap quality compounder stock; MCK is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.